Details for Patent: RE40000

US RE40000 (Carvedilol + Concomitant CHF Agents): Scope, Claims, and Patent Landscape

What is US RE40000 and what does it claim?

US RE40000 is a reissue patent directed to a method to decrease mortality caused by congestive heart failure (CHF) by administering carvedilol in combination with one or more standard CHF therapeutic agents and maintaining a daily regimen for longer than six months.

The independent claim anchors the scope on four elements:

• Indication: “a patient in need thereof” with congestive heart failure
• Core drug: carvedilol
• Combination requirement: carvedilol is given “in conjunction with one or more other therapeutic agents” selected from:
  • ACE inhibitor (ACE)
  • diuretic
  • digoxin
• Duration: dosing is “daily maintenance dosages for a maintenance period” that is greater than six months
• Outcome linkage: intended use is “to decrease a risk of mortality caused by congestive heart failure”

Claim set (as provided)

How broad is the scope (and where does it contract)?

High-level scope drivers (broad)

1. Combination choice is flexible. Claim 1 requires “one or more other therapeutic agents” from a defined group. That means a regimen can include:
   • only an ACE inhibitor, or
   • only a diuretic, or
   • only digoxin, or
   • any combination of those within the set.
2. Duration is binary and long-form. “Maintenance period is greater than six months” sets a threshold that is straightforward to test and enforce (use beyond 6 months).
3. CHF severity range is included. Claim 9 covers NYHA class II-IV (as framed by “class II-IV congestive heart failure”).

Scope contraction points (narrower)

1. Carvedilol dosing is constrained by dependent claims. While Claim 1 does not itself specify a dose, Claims 2 to 5 set specific dosage ranges and patient weight rules that can constrain practicing variants if those dependents are asserted.
2. Specific ACE inhibitor and diuretic identities appear in dependents.
   • ACE inhibitor in Claim 6 is limited to captopril/lisinopril/enalapril (or salts).
   • Diuretic in Claim 7 is limited to hydrochlorothiazide/furosemide (or salts).
3. Statistical support language in Claim 8. Claim 8 requires that dosages and period “have been shown” to decrease mortality risk statistically. That language affects claim interpretation and may be used to tie the invention to trial-supported regimens rather than any theoretical decrease.

What exactly must be done to infringe (element-by-element)?

Under the literal language supplied, a practicing method must match these structural elements:

1. Patient selection

   • The patient must be in need of therapy for CHF (and if Claim 9 is asserted, the patient is class II-IV).

2. Therapeutic regimen

   • The method administers carvedilol.
   • The administration is “in conjunction with one or more other therapeutic agents” selected from ACE inhibitor, diuretic, and digoxin.

3. Maintenance dosing

   • The method requires daily maintenance dosages (not intermittent dosing).
   • The maintenance must run for a maintenance period > six months.

4. Intended effect

   • The method “decrease[s] a risk of mortality caused by CHF.” In enforcement, this becomes a claim-construction and proof issue, but the scope language is explicit.

5. If asserted dependent claims apply

   • Carvedilol regimen is 3.125 to 50 mg BID (Claim 2), or fixed 25 mg BID (Claim 3), or 25 to 50 mg BID for patients >85 kg (Claim 4), or 50 mg BID for patients >85 kg (Claim 5).
   • ACE inhibitor must be captopril/lisinopril/enalapril (Claim 6) if Claim 6 is used to narrow.
   • Diuretic must be hydrochlorothiazide or furosemide (Claim 7) if Claim 7 is used.

Where does the claim language land relative to standard CHF therapy?

The combination of carvedilol with ACE inhibitor / diuretic / digoxin aligns with the conventional CHF pharmacotherapy framework. The enforceable differentiator is the mortality decrease method framing plus the maintenance period threshold (>6 months) and the dependent specific dosing and patient weight rules.

From a scope perspective:

• If carvedilol is used for CHF but not for a regimen extending beyond six months as a “maintenance” mortality-decreasing regimen, that may fall outside Claim 1’s explicit “maintenance period greater than six months.”
• If carvedilol is used with ACE inhibitor/diuretic/digoxin outside the defined group, Claim 1’s combination element may not be met.
• If the combination uses an ACE inhibitor other than captopril/lisinopril/enalapril, it may avoid the narrow dependents but can still fall under Claim 1 if the “ACE inhibitor” category is interpreted broadly in Claim 1 (Claim 6 is narrower than Claim 1’s ACE category).

What is the likely patent landscape shape around RE40000?

Even without relying on external prosecution history, RE40000’s claim architecture indicates it sits in a crowded carve-up of:

• carvedilol CHF efficacy and dosing, and
• CHF combination regimens with ACE inhibitors and/or diuretics and/or digoxin,
• duration-based maintenance concepts, and
• mortality-risk framing.

Landscape segmentation for business planning

1. Carvedilol CHF regimen patents

   • Expected to include method claims tied to mortality or morbidity endpoints and dose schedules (including titration and maintenance).
   • Dependent claims here suggest the assignee sought enforceable “dose bands” and “fixed-dose” embodiments.

2. Combination therapy patents (beta-blocker + ACE/diuretic/digoxin)

   • Claim 1’s list-based structure implies known background therapy categories were used, while the inventors tried to lock the patent to carvedilol’s role and the required duration.

3. Endpoint and duration patents

   • The “maintenance period > six months” and “statistically decrease” language signal the applicant aimed to distinguish by tying effect to a longer maintenance horizon.

How RE40000 would be searched in freedom-to-operate

A practical search query map based on claim language:

• Carvedilol AND congestive heart failure AND mortality
• Carvedilol AND (ACE inhibitor OR enalapril OR lisinopril OR captopril) AND CHF
• Carvedilol AND digoxin AND mortality AND CHF
• Carvedilol AND diuretic AND CHF AND maintenance period
• Carvedilol 3.125 AND 50 mg AND twice daily
• Carvedilol 25 mg BID AND class II-IV CHF

Key litigation/clearance risk points for competitors

The risk is highest where a competitor’s marketed method (or label-directed regimen) aligns with:

• Daily carvedilol maintenance in CHF with at least one of the specified co-therapies, and
• Treatment beyond 6 months, and
• The patient profile overlaps with dependent claim boundaries (notably the >85 kg weight rule), and
• The regimen matches the dependent dose schedule asserted.

How do the dependent claims affect enforceability strategy?

RE40000’s dependent claims create a layered infringement strategy:

• Claim 1 is the broadest independent anchor.
• Claims 2-5 add dose precision and a weight predicate.
• Claims 6-7 add explicit drug identity constraints for ACE and diuretic options.
• Claim 8 adds a “shown statistically” framing that may be used to connect the claimed method to efficacy evidence used during prosecution.
• Claim 9 adds CHF class limitation.

This layering impacts settlement posture: plaintiffs can select the easiest-to-prove narrower dependent claim depending on regimen facts and patient populations.

What are the main “design-around” pathways in scope terms?

Given the claim text, the main levers are:

1. Combination composition
   • Use carvedilol with CHF therapy that does not include any of the categories as claimed (not simply “other CHF agents,” but excluding ACE inhibitors, diuretics, and digoxin). This is difficult in real-world CHF practice because these categories are common.
2. Duration and maintenance
   • Avoid the “maintenance period greater than six months” framing by using carvedilol in a regimen not characterized as maintenance beyond six months, which is unlikely in chronic CHF therapy.
3. Dosing
   • Move outside dependent dose bands (Claims 2-5), especially the weight-specific dosing (Claims 4-5). Claim 1 still lacks a dose range, so dose changes alone may not escape Claim 1.
4. Patient class
   • Treat only outside “class II-IV” to avoid Claim 9, though Claim 1 does not limit class by itself.

Key Takeaways

• US RE40000 is a CHF mortality-decrease method patent anchored on carvedilol + at least one of ACE inhibitor, diuretic, or digoxin, with daily maintenance dosing for >6 months.
• Dependent claims narrow the enforceable scope to specific carvedilol dose ranges (including BID dosing up to 50 mg), weight-based dosing for patients >85 kg, and specific ACE inhibitors and diuretics (captopril/lisinopril/enalapril; hydrochlorothiazide/furosemide).
• Enforcement leverage is strongest where a regimen matches chronic CHF maintenance beyond six months and uses the common co-therapies named in Claim 1, with patient cohorts and dosing matching dependent limitations.

FAQs

1) Does RE40000 require ACE inhibitor, diuretic, and digoxin all together?

No. Claim 1 requires “one or more other therapeutic agents” from the group consisting of ACE inhibitor, diuretic, and digoxin. Any single agent from that set, or a combination, can satisfy the “one or more” language.

2) What is the single most critical time limitation in the claims?

Claim 1 requires a maintenance period greater than six months.

3) Is the carvedilol dose mandatory under Claim 1?

Claim 1 requires carvedilol but does not itself state a numeric dose. Numeric dose limitations appear in dependent claims (2 to 5).

4) How do the weight limits work?

Claims 4 and 5 restrict certain carvedilol maintenance doses to patients whose weight exceeds about 85 kg.

5) Which ACE inhibitors and diuretics are explicitly covered in the provided dependents?

ACE inhibitor is limited in Claim 6 to captopril, lisinopril, enalapril (or salts). Diuretic is limited in Claim 7 to hydrochlorothiazide and furosemide (or salts).

References

[1] RE40000 patent claims (user-provided text).